drugset / Trial / NCT02025712
Exemestane Plus Everolimus for Hormone-receptor Positive Metastatic Breast Cancer
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to determine whether exemestane plus everolimus are effective in the treatment of patients who have achieved disease stabilization after induction chemotherapy for hormone-receptor positive metastatic breast cancer.
Timeline
- Start
- —
- Primary completion
- 2016-08
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Everolimus | Small molecule | 10 mg | Oral |
| Subject | Exemestane | Small molecule | 25 mg | — |